Howard McLeod

Citada per

	Totes	Des de 2020
Citacions	57655	13503
Índex h	122	53
Índex i10	507	258

3000

1500

750

2250

199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025199 308 429 731 910 1485 1671 2247 2254 2466 2362 2586 2694 2917 2893 2971 2892 2745 2729 2701 2808 2830 2949 2692 2406 2305 309

Accés públic

Mostra-ho tot

194 articles

31 articles

disponibles

no disponibles

Es basa en els requisits de les agències que proporcionen el finançament

Coautors

Teri E. KleinStanford UniversityCorreu electrònic verificat a stanford.edu
Mark RatainLeon O. Jacobson Professor of Medicine, The University of ChicagoCorreu electrònic verificat a uchicago.edu
Alison Motsinger-ReifNational Institute of Environmental Health SciencesCorreu electrònic verificat a nih.gov
Richard Goldberg MDProfessor emeritus, West Virginia UniversityCorreu electrònic verificat a hsc.wvu.edu
Mary V. RellingSt. Jude Children's Research HospitalCorreu electrònic verificat a stjude.org
Daniel L HertzUniversity of MichiganCorreu electrònic verificat a med.umich.edu
William E EvansSt. Jude Children's Research HospitalCorreu electrònic verificat a stjude.org
Brian F. GageProfessor of Medicine, Washington University in St. LouisCorreu electrònic verificat a im.wustl.edu
LISA A. CAREY MD, ScM, FASCOUniversity of North Carolina Lineberger Comprehensive Cancer CenterCorreu electrònic verificat a med.unc.edu
Russ B AltmanProfessor Stanford UniversityCorreu electrònic verificat a stanford.edu
Deepak VooraDepartment of Veterans Affairs; Duke University Medical CenterCorreu electrònic verificat a duke.edu
Jai N. Patel, PharmD, BCOP, CPPChair, Cancer Pharmacology & Pharmacogenomics, Levine Cancer Institute, Atrium HealthCorreu electrònic verificat a atriumhealth.org
Todd C. KnepperAssociate Member, Precision Medicine, Moffitt Cancer CenterCorreu electrònic verificat a moffitt.org
Jaap VerweijErasmus University Medical Center and Cancer Drug Development ForumCorreu electrònic verificat a cddf.org
David Ofori-AdjeiProfessor of Medicine & Therapeutics, University of GhanaCorreu electrònic verificat a noguchi.ug.edu.gh
David E. LanfearHenry Ford HospitalCorreu electrònic verificat a hfhs.org
E Claire DeesUNCCorreu electrònic verificat a med.unc.edu
John SpertusSaint Luke's Mid America Heart Institute/University of Missouri - Kansas CityCorreu electrònic verificat a umkc.edu
Derek Van BoovenDirector Research Data, John P Hussman Insitute for Human Genomics, University of MiamiCorreu electrònic verificat a med.miami.edu
Frank J. GonzalezNational Cancer InstituteCorreu electrònic verificat a mail.nih.gov

Segueix

Howard McLeod

Utah Tech University

Correu electrònic verificat a utahtech.edu - Pàgina d'inici

personalized medicine cancer genomics Pharmacogenomics


Títol Ordena per cites Ordena per any Ordena per títol	Citada per Citada per	Any
Pharmacogenomics—drug disposition, drug targets, and side effects WE Evans, HL McLeod New England journal of medicine 348 (6), 538-549, 2003	2540	2003
Doxorubicin pathways: pharmacodynamics and adverse effects CF Thorn, C Oshiro, S Marsh, T Hernandez-Boussard, H McLeod, ... Pharmacogenetics and genomics 21 (7), 440-446, 2011	2119	2011
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose MJ Rieder, AP Reiner, BF Gage, DA Nickerson, CS Eby, HL McLeod, ... New England Journal of Medicine 352 (22), 2285-2293, 2005	1847	2005
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ... Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008	1006	2008
Genomics and drug response L Wang, HL McLeod, RM Weinshilboum New England Journal of Medicine 364 (12), 1144-1153, 2011	779	2011
Platinum neurotoxicity pharmacogenetics SR McWhinney, RM Goldberg, HL McLeod Molecular cancer therapeutics 8 (1), 10-16, 2009	729	2009
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update U Amstutz, LM Henricks, SM Offer, J Barbarino, JHM Schellens, JJ Swen, ... Clinical Pharmacology & Therapeutics 103 (2), 210-216, 2018	630	2018
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs S Zhou, SY Chan, BC Goh, E Chan, W Duan, M Huang, HL McLeod Clinical pharmacokinetics 44, 279-304, 2005	620	2005
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity MM Ameyaw, F Regateiro, T Li, X Liu, M Tariq, A Mobarek, N Thornton, ... Pharmacogenetics and Genomics 11 (3), 217-221, 2001	610	2001
UGT1A1* 28 genotype and irinotecan-induced neutropenia: dose matters JM Hoskins, RM Goldberg, P Qu, JG Ibrahim, HL McLeod Journal of the National Cancer Institute 99 (17), 1290-1295, 2007	583	2007
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer Y Wang, T Jatkoe, Y Zhang, MG Mutch, D Talantov, J Jiang, HL McLeod, ... Journal of clinical oncology 22 (9), 1564-1571, 2004	579	2004
PI3K/Akt/mTOR pathway as a target for cancer therapy D Morgensztern, HL McLeod Anti-cancer drugs 16 (8), 797-803, 2005	574	2005
Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia HL McLeod, EY Krynetski, MV Relling, WE Evans Leukemia 14 (4), 567-572, 2000	572	2000
Carbamazepine, HLA-B1502* and Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: US FDA Recommendations PB Ferrell, HL McLeod Pharmacogenomics 9 (10), 1543-1546, 2008	509	2008
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism GJ Peters, HHJ Backus, S Freemantle, B Van Triest, G Codacci-Pisanelli, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1587 (2-3 …, 2002	506	2002
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine AJ Black, HL McLeod, HA Capell, RH Powrie, LK Matowe, SC Pritchard, ... Annals of internal medicine 129 (9), 716-718, 1998	492	1998
Strategies for enzyme/prodrug cancer therapy G Xu, HL McLeod Clinical Cancer Research 7 (11), 3314-3324, 2001	487	2001
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study JG Scott, A Berglund, MJ Schell, I Mihaylov, WJ Fulp, B Yue, E Welsh, ... The lancet oncology 18 (2), 202-211, 2017	481	2017
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update LB Ramsey, SG Johnson, KE Caudle, CE Haidar, D Voora, RA Wilke, ... Clinical Pharmacology & Therapeutics 96 (4), 423-428, 2014	478	2014
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. X Wei, HL McLeod, J McMurrough, FJ Gonzalez, P Fernandez-Salguero The Journal of clinical investigation 98 (3), 610-615, 1996	477	1996

En aquests moments el sistema no pot dur a terme l'operació. Torneu-ho a provar més tard.

Articles 1–20

Cites per any

Cites duplicades

Cites combinades

Addició de coautorsCoautors

Segueix

Citada per

Coautors